Cocaine

Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia

Retrieved on: 
Thursday, February 29, 2024

The presentation will include additional data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.

Key Points: 
  • The presentation will include additional data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

Latest Holistic Approach for those Struggling With Chemical Dependency

Retrieved on: 
Friday, February 23, 2024

The effects of this active metabolite begin to peak within a week after treatment, based upon past patients’ reports of improved cognitive functioning.

Key Points: 
  • The effects of this active metabolite begin to peak within a week after treatment, based upon past patients’ reports of improved cognitive functioning.
  • Informative data stems from metabolic data collected before ibogaine treatment and once more in the days to follow.
  • Results from twenty patients indicate smooth stabilization, indicating safety and efficacy of the active metabolite.
  • Thorough monitoring is crucial for sustained success, but the long-term effectiveness of noribogaine necessitates follow-up updates in subsequent months.

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

Retrieved on: 
Thursday, February 22, 2024

GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes. Schedule I Substances include Psilocybin, psilocybin, mescaline, peyote, ibogaine Schedule II Substances: Opium, poppy straw, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, opium straw concentrates, pending: erythroxylon coca (cocaine)

Key Points: 
  • Achieving this substantial approval allows Bright Green to bring their deep expertise to these issues to help propel our Drugs Made in America movement forward.
  • The research will be conducted the Company’s C2 team in Albuquerque, New Mexico, and the reshoring of production and manufacturing to the U.S. will take place at the company’s Grants, New Mexico facility.
  • Medical plants will be produced in climate-controlled glass greenhouses engineered to ensure quality and predictability, laying a roadmap for guaranteed supply contracts with both federal government entities and other pharmaceutical interests.
  • Bright Green expects to be the first company in almost 100 years to produce, manufacture and supply API for Schedule I and Schedule II controlled substances and to deliver on contracts of this type.

Drug Abuse Testing Market, Size, Global Forecast Report 2024-2030: Focus on Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, and LSD - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024

Drug of Abuse Testing Market size is expected to hit US$ 10.28 Billion by 2030 from US$ 6.18 Billion in 2023.

Key Points: 
  • Drug of Abuse Testing Market size is expected to hit US$ 10.28 Billion by 2030 from US$ 6.18 Billion in 2023.
  • Innovations in technology are continuously emerging to expedite and enhance drug testing efficiency in response to the growing demand for such services.
  • The drug abuse testing market is generally pushed by strict laws that mandate drug abuse testing, growing government initiatives concerning drug abuse, rising consumption of alcohol and different drugs, and growing mortality because of drugs.
  • The growing global population engaged in alcohol and illicit drug use, encompassing substances like marijuana and cocaine, drives the drug abuse testing market's growth.

Methamphetamine Use Reaches All-Time High in People Who Use Fentanyl with No Signs of Slowing, Adding Fuel to U.S. Fentanyl Crisis

Retrieved on: 
Wednesday, February 21, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240220752791/en/
    Shifting trends in the co-detection of prescription opioids, heroin, methamphetamine, and cocaine nationally provide insight into how each has changed over time.
  • More recently, a fourth wave of overdose deaths co-involving fentanyl with stimulants like methamphetamine and cocaine has emerged.
  • Stimulants were co-involved in over 30% of fentanyl overdose deaths in 2021, up from less than 1% in 2010.
  • Millennium Health’s Signals Report shows that UDT data tightly correlate with U.S. overdose mortality rates and closely follow the evolution of America’s fentanyl crisis.

More Than 400,000 Animals Assisted by ASPCA Animal Poison Control Center in 2023

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ -- Today, the ASPCA® (The American Society for the Prevention of Cruelty to Animals®) Animal Poison Control Center (APCC) announced its annual list of top toxins for pets ahead of National Poison Prevention Week (March 17 – 23). In 2023, the APCC team of 163 veterinary professionals – including 22 board-certified veterinary toxicologists– helped more than 400,000 animals from across all 50 states.

Key Points: 
  • NEW YORK, March 5, 2024 /PRNewswire/ -- Today, the ASPCA® (The American Society for the Prevention of Cruelty to Animals®) Animal Poison Control Center (APCC) announced its annual list of top toxins for pets ahead of National Poison Prevention Week (March 17 – 23).
  • In 2023, the APCC team of 163 veterinary professionals – including 22 board-certified veterinary toxicologists– helped more than 400,000 animals from across all 50 states.
  • "Veterinary experts at the ASPCA Poison Control Center see a steady increase in call volume each year, which reflects an increased recognition of items that pose a potential risk to pets," said Dr. Tina Wismer, Senior Director of Toxicology, ASPCA Animal Poison Control Center.
  • For more information about the ASPCA Animal Poison Control Center, please visit www.aspca.org/poison .

She Lived As A Lesbian And Male Impersonator Until She Saw God's Plans For Her Life

Retrieved on: 
Monday, March 4, 2024

HOMESTEAD, Fla., March 4, 2024 /PRNewswire-PRWeb/ -- Author Miriam Passmore tells how her life was forever changed after she met the Lord, and accepted The Confirmation Of A Divine Call ($10.99, paperback, 9781662876936; $4.99, e-book, 9781662876943).

Key Points: 
  • I know He can do it for someone else
    Before she was delivered, Passmore was miserable.
  • She escaped her unhappy life with cocaine and alcohol, and struggled with suicidal thoughts because she did not want to be gay.
  • She experienced godly love through a prayer group filled with Christian men who encouraged her, and she eventually found peace through Jesus Christ.
  • She has appeared on The 700 Club, an affiliate of TBN, Atlanta 57, and several magazines, local radio and Christian stations.

Anonymous Health Expands Innovative Addiction Care Services to Oregon

Retrieved on: 
Wednesday, February 21, 2024

PORTLAND, Ore., Feb. 21, 2024 /PRNewswire/ -- Anonymous Health, a pioneer in outpatient teletherapy services, is proud to announce its statewide expansion across Oregon.

Key Points: 
  • PORTLAND, Ore., Feb. 21, 2024 /PRNewswire/ -- Anonymous Health, a pioneer in outpatient teletherapy services, is proud to announce its statewide expansion across Oregon.
  • "We are excited to help address long-standing capacity and access challenges of addiction care in Oregon, including in rural communities," said Medical Director, Dr. Palani Chidambaram.
  • "(1) Dr. Chidambaram is Board certified in Internal Medicine and Addiction Medicine, and he founded and leads the addiction medicine practice at several Providence Health System hospitals in the Portland, Oregon region.
  • Personalized Care and Advanced Technology: Anonymous Health's Approach
    Patients at Anonymous Health receive near-immediate attention from a dedicated Concierge Care Manager.

Too much heat in the kitchen: survey shows toxic work conditions mean many chefs are getting out

Retrieved on: 
Friday, March 8, 2024

“Chefs, chefs, chefs!

Key Points: 
  • “Chefs, chefs, chefs!
  • Australia is seeing a similar gap, with chefs ranked the eighth most in-demand occupation.
  • Our study is the first quantitative survey to examine working conditions and mental health issues among chefs in both Australia and New Zealand.
  • The survey also followed up previous Australian studies, which indicated exploitation was an industry norm, with chefs experiencing burnout and wage theft.

‘Banter, bollockings and beatings’

  • As one British study titled “Banter, bollockings and beatings” made clear, an often macho culture can prevail, including bizarre induction rituals.
  • An Australian study published in 2022 showed chefs were significantly more likely than the general population to commit suicide.
  • And even before the pandemic, the industry’s “toxic” workplace culture was blamed for mental health issues and high suicide rates among employees.
  • Two-thirds (67%) of respondents worked more than 38 hours weekly, but a fifth of the chefs worked 52-61 hours.

Leaving the industry

  • Results showed high levels of physical and mental fatigue (“exhausted at work”, “emotionally drained”, “becoming disconnected”).
  • The majority of respondents said they were likely (with 20% extremely likely) to look for a new employer during the next year.
  • Read more:
    All these celebrity restaurant wage-theft scandals point to an industry norm

Mental health and healthy hospo

  • The Better Work Action Plan, the first phase of New Zealand’s Tourism Industry Transformation Plan, was launched by MBIE in 2023 under the previous government.
  • It followed extensive consultation with representatives from hospitality and tourism, Māori, unions, workers and government.
  • Its aim was to develop a sustainable tourism workforce by addressing longstanding issues of low pay and poor conditions across the sector.
  • By chance, however, New Zealand’s new minister for mental health, Matt Doocey, is also tourism and hospitality minister.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.